Bristol Myers Squibb (BMY) Revenue (2009 - 2025)

Bristol Myers Squibb (BMY) has 17 years of Revenue data on file, last reported at $48.2 billion in FY2025.

• Revenue for Q1 2026 came in at $11.5 billion, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 billion (up 1.78% YoY), and the FY2025 annual result was $48.2 billion, changed 0.22% from the prior year.
• Revenue was little changed at $48.2 billion in FY2025 per BMY's latest filing, from $48.3 billion in the prior year.
• Over five years, Revenue peaked at $48.3 billion in FY2024 and troughed at $45.0 billion in FY2023.
• A 5-year average of $46.8 billion and a median of $46.4 billion in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2021 and 2023: Revenue rose 9.09% in 2021, then dropped 2.5% in 2023.
• A 5-year view of Revenue shows it stood at $46.4 billion in 2021, then dropped by 0.49% to $46.2 billion in 2022, then slipped by 2.5% to $45.0 billion in 2023, then rose by 7.32% to $48.3 billion in 2024, then decreased by 0.22% to $48.2 billion in 2025.
• Business Quant data shows BMY's Revenue at $48.2 billion in FY2025, $48.3 billion in FY2024, and $45.0 billion in FY2023.